Literature DB >> 19463229

[Update on the treatment of alopecia areata].

M Galán-Gutiérrez1, A Rodríguez-Bujaldón, J C Moreno-Giménez.   

Abstract

Alopecia areata is nonscarring telogenic alopecia of autoimmune etiology. It is estimated to be the presenting complaint in 2 % of dermatologic consultations, and can appear at any age although it is more common in young patients. Treatment depends on several factors, such as extent of the disease and age, and may be local or systemic. Local treatments aim to achieve hair regrowth, but do not alter the underlying condition, whereas systemic treatments can modify the course of the disease. In neither case does treatment provide a cure. In this article, we review most of the therapeutic options described in the literature for alopecia areata.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19463229

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  3 in total

1.  Association between PTPN22 C1858T polymorphism and alopecia areata risk.

Authors:  Mauricio Salinas-Santander; Celia Sánchez-Domínguez; Cristina Cantú-Salinas; Hugo Gonzalez-Cárdenas; Ana Cecilia Cepeda-Nieto; Ricardo M Cerda-Flores; Rocío Ortiz-López; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2015-09-04       Impact factor: 2.447

2.  Hair regrowth in alopecia areata patients following Stem Cell Educator therapy.

Authors:  Yanjia Li; Baoyong Yan; Hepeng Wang; Heng Li; Quanhai Li; Dong Zhao; Yana Chen; Ye Zhang; Wenxia Li; Jun Zhang; Shanfeng Wang; Jie Shen; Yunxiang Li; Edward Guindi; Yong Zhao
Journal:  BMC Med       Date:  2015-04-20       Impact factor: 8.775

3.  The association between rs2476601 polymorphism in PTPN22 gene and risk of alopecia areata: A meta-analysis of case-control studies.

Authors:  Zi-Xian Lei; Wen-Jing Chen; Jun-Qin Liang; Yan-Jun Wang; Lan Jin; Chen Xu; Xiao-Jing Kang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.